ES2219926T3 - Composiciones y metodos para el tratamiento del trastorno deficitario de la atencion y del trastorno de la hiperactividad con deficit de la atencion por medio de metilfenidato. - Google Patents

Composiciones y metodos para el tratamiento del trastorno deficitario de la atencion y del trastorno de la hiperactividad con deficit de la atencion por medio de metilfenidato.

Info

Publication number
ES2219926T3
ES2219926T3 ES98963170T ES98963170T ES2219926T3 ES 2219926 T3 ES2219926 T3 ES 2219926T3 ES 98963170 T ES98963170 T ES 98963170T ES 98963170 T ES98963170 T ES 98963170T ES 2219926 T3 ES2219926 T3 ES 2219926T3
Authority
ES
Spain
Prior art keywords
methylphenidate
polymer
composition according
weight
natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98963170T
Other languages
English (en)
Spanish (es)
Inventor
Juan Mantelle
Terese A. Dixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noven Pharmaceuticals Inc
Original Assignee
Noven Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26750154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2219926(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noven Pharmaceuticals Inc filed Critical Noven Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2219926T3 publication Critical patent/ES2219926T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
ES98963170T 1997-12-15 1998-12-14 Composiciones y metodos para el tratamiento del trastorno deficitario de la atencion y del trastorno de la hiperactividad con deficit de la atencion por medio de metilfenidato. Expired - Lifetime ES2219926T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6951097P 1997-12-15 1997-12-15
US69510P 1997-12-15
US163351 1998-09-30
US09/163,351 US6210705B1 (en) 1997-12-15 1998-09-30 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate

Publications (1)

Publication Number Publication Date
ES2219926T3 true ES2219926T3 (es) 2004-12-01

Family

ID=26750154

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10011358.8T Expired - Lifetime ES2452517T3 (es) 1997-12-15 1998-12-14 Composiciones y métodos para el tratamiento del trastorno de déficit de atención y del trastorno de déficit de atención e hiperactividad con metilfenidato
ES98963170T Expired - Lifetime ES2219926T3 (es) 1997-12-15 1998-12-14 Composiciones y metodos para el tratamiento del trastorno deficitario de la atencion y del trastorno de la hiperactividad con deficit de la atencion por medio de metilfenidato.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES10011358.8T Expired - Lifetime ES2452517T3 (es) 1997-12-15 1998-12-14 Composiciones y métodos para el tratamiento del trastorno de déficit de atención y del trastorno de déficit de atención e hiperactividad con metilfenidato

Country Status (28)

Country Link
US (2) US6210705B1 (enExample)
EP (2) EP2314288B1 (enExample)
JP (3) JP4316800B2 (enExample)
KR (1) KR100633348B1 (enExample)
CN (1) CN1368876A (enExample)
AR (1) AR014062A1 (enExample)
AT (1) ATE260652T1 (enExample)
AU (1) AU752027B2 (enExample)
BR (1) BR9814282A (enExample)
CA (1) CA2315237C (enExample)
CZ (2) CZ300535B6 (enExample)
DE (1) DE69822199T2 (enExample)
DK (1) DK1037615T3 (enExample)
ES (2) ES2452517T3 (enExample)
HK (1) HK1049447A1 (enExample)
HU (1) HU226615B1 (enExample)
IL (1) IL136760A0 (enExample)
LV (1) LV12558B (enExample)
NO (1) NO329974B1 (enExample)
NZ (1) NZ505689A (enExample)
PE (1) PE20000120A1 (enExample)
PL (1) PL195315B1 (enExample)
PT (1) PT1037615E (enExample)
RU (1) RU2233156C2 (enExample)
SI (1) SI20360B (enExample)
TR (1) TR200001736T2 (enExample)
TW (2) TWI244396B (enExample)
WO (1) WO1999030694A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
CO5261532A1 (es) * 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
ATE252903T1 (de) * 1999-12-17 2003-11-15 Celltech Pharma Europ Ltd Arzneimittel zur behandlung konvulsivischer zustände
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6905016B2 (en) * 2000-03-14 2005-06-14 Noven Pharmaceuticals, Inc. Packaging system for transdermal drug delivery systems
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
BR0207955A (pt) * 2001-03-07 2004-02-25 Hisamitsu Pharmaceutical Co Agente de emplastro
FR2822049B1 (fr) * 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
ATE364380T1 (de) * 2001-03-16 2007-07-15 Alza Corp Transdermales pflaster zur verabreichung von fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
HUE026034T2 (en) 2002-12-13 2016-05-30 Durect Corp Oral delivery system containing an oral high-viscosity carrier
AU2004285505B2 (en) * 2003-10-28 2010-12-23 Noven Pharmaceuticals, Inc. Transdermal drug delivery device
WO2006078984A2 (en) * 2005-01-20 2006-07-27 Institute For Molecular Medicine, Inc. Uses of methylphenidate derivatives
KR101318806B1 (ko) 2005-01-20 2013-10-16 인스티튜트 포 몰리큘러 메디신, 인코포레이티드 메틸페니데이트 유도체 및 그 용도
US9393218B2 (en) * 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
MX2008008211A (es) * 2005-12-23 2008-09-03 Epinamics Gmbh Uso de polimeros para el cuidado del cabello formando peliculas del grupo de los poliuretanos y preparaciones farmaceuticas y parches conteniendo estos polimeros.
CA2643037C (en) * 2006-02-27 2014-08-05 Noven Pharmaceuticals, Inc. Compositions and methods for delivery of amino-functional drugs
MX2008013613A (es) * 2006-05-01 2008-10-30 Colgate Palmolive Co Composicion para el cuidado oral con compuesto de silicona.
US20100104621A1 (en) * 2007-02-21 2010-04-29 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
KR101583680B1 (ko) * 2007-10-15 2016-01-08 알자 코퍼레이션 펜타닐의 1일-1회 교체 경피 투여
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
FR2924350B1 (fr) * 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
JP2011506318A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 経口医薬製剤
US8795713B2 (en) * 2007-12-31 2014-08-05 Acclarent, Inc. Mucosal tissue dressing and method of use
FR2926466B1 (fr) * 2008-01-23 2010-11-12 Dbv Tech Procede de fabrication de patchs par electrospray
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5155128B2 (ja) * 2008-12-11 2013-02-27 日東電工株式会社 メチルフェニデート貼付製剤
EP2942196B8 (en) * 2009-06-05 2018-01-10 Babcock & Wilcox MEGTEC, LLC Improved infrared float bar
EP2364695A1 (en) 2010-02-10 2011-09-14 Nitto Denko Corporation Methylphenidate patch preparation
US20110200663A1 (en) * 2010-02-12 2011-08-18 Nitto Denko Corporation Methylphenidate patch preparation
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
EP4316488A3 (en) 2011-03-23 2024-02-28 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
PH12014500049A1 (en) 2011-07-28 2016-07-29 Kempharm Inc Methylphenidate-prodrugs, processes of making and using the same
CA2891467A1 (en) 2012-10-15 2014-04-24 Noven Pharmaceuticals, Inc. Compositions and methods for the transdermal delivery of methylphenidate
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
AR094289A1 (es) 2012-12-28 2015-07-22 Noven Pharma Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
JP6359032B2 (ja) 2012-12-28 2018-07-18 ノーヴェン ファーマシューティカルズ インコーポレイテッド 経皮薬物送達用のマルチポリマー組成物
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2014159582A1 (en) 2013-03-14 2014-10-02 Noven Pharmaceuticals, Inc Amphetamine transdermal compositions with acrylic block copolymer
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
AR095260A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones de anfetaminas transdérmicas estables y métodos de fabricación
US9782383B2 (en) 2013-12-25 2017-10-10 Fujimoto Co., Ltd. Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
CN106511264A (zh) * 2016-11-15 2017-03-22 北京万全德众医药生物技术有限公司 一种盐酸哌甲酯口服溶液剂及其制备方法
BR112019011640B1 (pt) 2016-12-11 2021-08-17 Kempharm, Inc Compostos conjugados de d-metilfenidato, composições que compreendem os mesmos e kit farmacêutico que compreende as ditas composições
EP3598982A1 (en) 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Bioconjugates of neuropeptides derivatives
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3910578A1 (de) * 1989-03-29 1990-10-04 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
JP2693212B2 (ja) * 1989-03-28 1997-12-24 日東電工株式会社 疾患治療用テープ製剤
WO1992021333A2 (en) * 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
US5629019A (en) 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
WO1994002176A1 (en) 1992-07-28 1994-02-03 The Procter & Gamble Company Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
CH691209A5 (de) 1993-09-06 2001-05-15 Scherrer Inst Paul Herstellungsverfahren für einen Polmerelektrolyten und elektrochemische Zelle mit diesem Polymerelektrolyten.
ES2139778T3 (es) 1994-06-29 2000-02-16 Hennecke Gmbh Procedimiento y dispositivo para la fabricacion continua de bloques o bandas de material de espuma.
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
WO1998039042A1 (en) 1997-03-07 1998-09-11 Jackson Richard R Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
GB9711032D0 (en) 1997-05-30 1997-07-23 Johnson Matthey Plc Compound as a stimulant for the central nervous system
EP1710506A2 (en) 1999-12-15 2006-10-11 Osaka Gas Co., Ltd. Burner Apparatus, Gas Turbine Engine and Cogeneration System

Also Published As

Publication number Publication date
SI20360A (sl) 2001-04-30
AU752027B2 (en) 2002-09-05
WO1999030694A3 (en) 1999-08-19
JP2002510600A (ja) 2002-04-09
HU226615B1 (en) 2009-04-28
ES2452517T3 (es) 2014-04-01
EP1037615B1 (en) 2004-03-03
TW200406231A (en) 2004-05-01
TR200001736T2 (tr) 2001-01-22
CZ300535B6 (cs) 2009-06-10
EP1037615A2 (en) 2000-09-27
CZ2009132A3 (cs) 2016-03-23
CA2315237A1 (en) 1999-06-24
BR9814282A (pt) 2000-10-03
JP4316800B2 (ja) 2009-08-19
EP2314288A1 (en) 2011-04-27
HK1156872A1 (en) 2012-06-22
LV12558A (lv) 2000-11-20
TWI244396B (en) 2005-12-01
CZ305817B6 (cs) 2016-03-23
PL341596A1 (en) 2001-04-23
DE69822199D1 (de) 2004-04-08
PE20000120A1 (es) 2000-02-19
LV12558B (en) 2001-03-20
AU1824999A (en) 1999-07-05
AR014062A1 (es) 2001-01-31
US6348211B1 (en) 2002-02-19
CN1368876A (zh) 2002-09-11
WO1999030694A2 (en) 1999-06-24
JP2009073856A (ja) 2009-04-09
EP2314288B1 (en) 2013-12-11
NO329974B1 (no) 2011-01-31
ATE260652T1 (de) 2004-03-15
PL195315B1 (pl) 2007-08-31
RU2233156C2 (ru) 2004-07-27
PT1037615E (pt) 2004-07-30
NO20003096L (no) 2000-08-15
IL136760A0 (en) 2001-06-14
HUP0004539A2 (hu) 2001-06-28
SI20360B (sl) 2008-06-30
KR100633348B1 (ko) 2006-10-16
HK1049447A1 (zh) 2003-05-16
HUP0004539A3 (en) 2006-06-28
CZ20002209A3 (cs) 2000-11-15
KR20010033114A (ko) 2001-04-25
JP2013056944A (ja) 2013-03-28
CA2315237C (en) 2009-12-01
NZ505689A (en) 2003-01-31
DE69822199T2 (de) 2005-02-17
NO20003096D0 (no) 2000-06-15
DK1037615T3 (da) 2004-07-12
TWI242452B (en) 2005-11-01
US6210705B1 (en) 2001-04-03

Similar Documents

Publication Publication Date Title
ES2219926T3 (es) Composiciones y metodos para el tratamiento del trastorno deficitario de la atencion y del trastorno de la hiperactividad con deficit de la atencion por medio de metilfenidato.
US20130324575A1 (en) Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
ES2285704T3 (es) Formulaciones nuevas para la administracion transdermica de pergolida.
JP3786684B2 (ja) オキシブチニンの経皮投与
ES2227707T3 (es) Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina.
ES2281641T3 (es) Sistema de administracion transdermica con dos capas adhesivas superpuestas que tienen diferente afinidad por la sustancia activa.
PT100502A (pt) Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
ES2219037T3 (es) Formulaciones para la administracion transdermica de fenoldopam.
EP1459741A1 (en) Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with menthylphenidate
HK1117745A (en) Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
HK1156872B (en) Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate